BMS’ Opdivo fails late-stage brain cancer testBristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo Share XBMS’ Opdivo fails late-stage brain cancer testhttps://pharmaphorum.com/news/bms-opdivo-fails-late-stage-brain-cancer-test/
Digital health round-up: Expert team prepares for digital transformation of NHS and moreEngland’s NHS is gearing up towards the ‘go live’ of a new digital transformation team that aims to Share XDigital health round-up: Expert team prepares for digital transformation of NHS and morehttps://pharmaphorum.com/views-analysis-digital/digital-health-round-up-expert-team-prepares-for-digital-transformation-of-nhs-and-more/
BMS and Concerto HealthAI sign real world evidence tie-upBristol-Myers Squibb and Concerto HealthAI, which specialises in using AI and machine learning technology to help generate ‘real Share XBMS and Concerto HealthAI sign real world evidence tie-uphttps://pharmaphorum.com/news/bms-and-concerto-healthai-sign-real-world-evidence-tie-up/
Doubts over BMS-Celgene merger after Starboard interventionDoubts are mounting about whether Bristol-Myers Squibb’s $74 billion merger with Celgene will go ahead after another key Share XDoubts over BMS-Celgene merger after Starboard interventionhttps://pharmaphorum.com/news/doubts-over-bms-celgene-merger-after-starboard-intervention/
Largest BMS shareholder opposes Celgene dealBristol-Myers Squibb’s (BMS) largest shareholder has come out against the company’s planned merger with Celgene, putting the future Share XLargest BMS shareholder opposes Celgene dealhttps://pharmaphorum.com/news/largest-bms-shareholder-opposes-celgene-deal/
Merck/Pfizer up the pressure on BMS in first-line kidney cancerThe FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney Share XMerck/Pfizer up the pressure on BMS in first-line kidney cancerhttps://pharmaphorum.com/news/merck-pfizer-up-the-pressure-on-bms-in-first-line-kidney-cancer/
BMS pulls Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line Share XBMS pulls Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
2019 M&A starts with a bang as BMS and Celgene agree $74bn mergerBristol-Myers Squibb has agreed a $74 billion deal to merge with Celgene in a deal that will boost Share X2019 M&A starts with a bang as BMS and Celgene agree $74bn mergerhttps://pharmaphorum.com/news/2019-ma-starts-with-a-bang-as-bms-agrees-74bn-merger-with-celgene/
